8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 20, 2008

PDI, INC.

(Exact name of Registrant as specified in its charter)

DELAWARE	0-24249	22-2919486
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

Saddle River Executive Centre

1 Route 17 South,

Saddle River, NJ 07458

(Address of principal executive offices and zip Code)

(201) 258-8450

Registrant's telephone number, including area code:

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     |_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     |_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     |_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     |_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Certain Officers; Election of Directors;Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On June 20, 2008, PDI, Inc. (the “Company”) issued a press release announcing the retirement of Michael J. Marquard as the Company’s Chief Executive Officer and as a member of the Company’s Board of Directors, effective immediately.  In connection with Mr. Marquard’s departure, the Company expects to make cash payments of approximately $869,000 to Mr. Marquard.  In addition, the Company has agreed to accelerate the vesting of 14,029 shares of common stock previously granted to Mr. Marquard.

Effective June 20, 2008, Jeffrey E. Smith, currently the Executive Vice President, Chief Financial Officer and Treasurer of the Company, has been appointed as interim Chief Executive Officer.  Mr. Smith, age 61, joined the Company as Executive Vice President, Chief Financial Officer and Treasurer in May 2006. Immediately prior to joining the Company, Mr. Smith was senior vice president, finance and chief financial officer of Pliva, Inc., a specialty generic pharmaceutical company. From 1985 to 2002, Mr. Smith served in various executive positions with Alpharma, Inc., a global specialty pharmaceutical company. While with Alpharma, Inc., Mr. Smith was executive vice president, finance and chief financial officer and, for a three-year period, was responsible for worldwide operations while serving as acting president and member of the office of the chief executive. Mr. Smith is a Certified Public Accountant who began his career with Coopers & Lybrand, now PricewaterhouseCoopers.  Mr. Smith received his B.S. from Fairleigh Dickinson University.

James G. Farrell, currently the Vice President, Corporate Controller of the Company, has been appointed as interim Chief Financial Officer of the Company, effective June 20, 2008.  Mr. Farrell, age 42, joined the Company in April 2008.  Prior to joining the Company, Mr. Farrell was the Vice President and Corporate Controller of Cambrex Corporation, a publicly traded global manufacturer and provider of services to life science companies.  From 1994 to 2005, Mr. Farrell served in various positions, including most recently as Director of Accounting Policy, Procedures and External Reporting, at Ingersoll-Rand Company, a publicly traded manufacturer of non-electric machinery and equipment with operations in over 250 locations worldwide.  Prior to that, Mr. Farrell was employed with Ernst & Young LLP.  Mr. Farrell is a Certified Public Accountant and received his B.S. from St. Thomas Aquinas College and an M.B.A. from Fordham University.

A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(c)              Exhibits

99.1   Press Release dated June 20, 2008.

                                  * * * * * * *

                                    SIGNATURE

      Pursuant to the requirements of the Securities Exchange Act of 1934, the

registrant has duly caused this report to be signed on its behalf by the

undersigned hereunto duly authorized.

           PDI, INC.

           By: /s/ James G. Farrell

           ------------------------------------

           James G. Farrell

          Chief Financial Officer

Date: June 26, 2008

EXHIBIT INDEX

Exhibit No.                                                      Description

___________                                                      ____________

99.1                                                      Press Release dated June 20, 2008

EXHIBIT 99.1

EX-99.1

PDI CONTACT:                                                                               INVESTOR CONTACTS:

Jeffrey E. Smith                                                                                  Lippert/Heilshorn & Associates, Inc.

Chief Financial Officer                                                                      Kim Sutton Golodetz (kgolodetz@lhai.com)

(201) 258-8451                                                                                    (212) 838-3777

jesmith@pdi-inc.com                                                                        Bruce Voss (bvoss@lhai.com)

www.pdi-inc.com                                                                               (310) 691-7100

PDI Announces Retirement of CEO

SADDLE RIVER, N.J. (June 20, 2008) – PDI, Inc. (NASDAQ: PDII), a provider of commercialization services to the biopharmaceutical industry, announced the retirement of Michael J. Marquard as Chief Executive Officer and as a member of the Company’s Board of Directors, effective today.  The Company will immediately begin a search for a new CEO.   While the search is underway, John P. Dugan, Chairman of the Board, former CEO and founder of the Company will play a more active role in overseeing operations.  Additionally, Jeffrey E. Smith, PDI’s Executive Vice President, Finance and Chief Financial Officer, has been named interim CEO.  Mr. Smith has more than 30 years of broad-based finance and general management experience including having served as interim President at Alpharma, Inc.  James Farrell, Vice President, Controller, will be assuming Mr. Smith’s CFO duties on an interim basis.

Mr. Dugan stated, “I would like to thank Mike for his dedicated service to PDI.  Working closely with the Board, Mike was instrumental in developing our strategic plan and the launch of many of the plan’s key initiatives.  The Board and the executive management team remain fully committed to the successful execution of this plan.  We wish Mike well in his retirement.”

Mr. Dugan continued, “We are fortunate to have someone with Jeff’s capabilities and experience to assume the role of interim CEO to lead PDI’s day-to-day operations until we have completed our search.  I am confident that Jeff and our seasoned and talented leadership team will continue with their excellent management of PDI.”

A CEO search committee headed by Jan Martens Vecsi, a member of PDI’s Board of Directors, has been formed and will engage the services of a retained search firm.  Ms. Vecsi has considerable experience hiring senior-level executives throughout a successful career including as senior human resources officer at Citibank.

About PDI

PDI provides commercialization services for established and emerging biopharmaceutical companies. The Company is dedicated to maximizing the return on investment for its clients by providing strategic flexibility, sales, marketing and commercialization expertise.

PDI currently operates in two business segments: Sales Services and Marketing Services.  Our Sales Services include Performance Sales Teams™, which are dedicated pharmaceutical sales force teams for specific customers; Select Access™, our targeted sales solution that leverages an existing sales force and infrastructure; and PDI ON DEMAND, a suite of innovative sales services that provide rapid, customized sales force solutions tailored to meet the local, regional and seasonal needs of our customers.  Our Marketing Services include marketing research and consulting services through TVG, and medical communications services through Pharmakon.  In addition, PDI is a high-quality provider of continuing medical education through Vital Issues in Medicine (VIM®).  PDI also provides Product Commercialization, where we utilize our considerable sales and marketing expertise to promote certain pharmaceutical products on behalf of our customers through revenue-sharing arrangements.  PDI's experience extends across multiple therapeutic categories and includes office- and hospital-based initiatives.

For more information, please visit the Company’s website at www.pdi-inc.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding future events and financial performance. These statements involve a number of risks and uncertainties and are based on numerous assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond PDI's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, the termination of or material reduction in the size of any of our customer contracts, the loss of our or our customers' intellectual property rights, our ability or inability to secure new business to offset the recent loss of customer contracts and the terms of any replacement business we secure, changes in our operating expenses, FDA, legal or accounting developments, competitive pressures, failure to meet performance benchmarks in significant contracts, changes in customer and market requirements and standards, the impact of any stock repurchase programs, the adequacy of the reserves PDI has taken, the financial viability of certain companies whose debt and equity securities we hold, the outcome of certain litigation, PDI's ability to implement its current and future business plans, and the risk factors detailed from time to time in PDI's periodic filings with the Securities and Exchange Commission, including without limitation, PDI's Annual Report on Form 10-K for the year ended December 31, 2007, and quarterly reports on Form 10-Q and current reports on Form 8-K. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. PDI undertakes no obligation to revise or update publicly any forward-looking statements for any reason.